Free Flap Reconstruction in the Era of Commercial Price Transparency – What are We Paying For?

Abstract

Background: Commercial rates for free flap reconstruction were not known publicly prior to the 2021 Hospital Price Transparency Final Rule. The purpose of this study was to examine commercial facility payments to characterize nationwide variation for microsurgical operations and identify opportunities to improve market effectiveness. Methods: A cross-sectional study was performed using 2022 commercial insurance pricing merged with hospital performance data. Facility payment rates were extracted for nine CPT codes for free flap operations. Price variation was quantified via across-hospital ratios (AHRs) and within-hospital ratios (WHRs). Mixed effects linear models evaluated commercial rates relative to value, outcomes, and equity performance metrics, in addition to facility-level factors that included healthcare market concentration. Results: 20,528 commercial rates across 675 hospitals were compiled. AHRs ranged from 5.85–7.95, while WHRs ranged from 1.00–1.71. Compared to the lowest scoring hospitals (grade D), hospitals with an outcome grade of A and equity grades of B or C were associated with higher commercial rates (p<0.04); there were no significant differences in rate based on value. Higher commercial rates were also associated with nonprofit status and more concentrated markets (p<0.006). Lower commercial rates were correlated with safety-net and teaching hospitals (p<0.001). Conclusion: Commercial rates for free flaps varied substantially both across and within hospitals. Associations of higher commercial rates with less competitive markets, and the lack of consistent association with value and equity, identify pricing failures. Additional work is needed to improve market efficiency for free flap operations.

Financial Toxicity in Breast Reconstruction: The Role of the Surgeon-Patient Cost-of-Care Discussion

“…4 17 18 19 20 The difficulty in navigating our health system whether insured or otherwise is demonstrated with the enactment of the Hospital Price Transparency Rule in 2021, where analysis of breast reconstruction pricing has suggested that privately insured patients are paying markedly different prices for breast reconstruction depending on insurer, plan, and hospital. 21 This systemic complexity both obscures patient interpretation of costs and creates barriers to providers in counseling their patients.…”

Discussion: Free Flap Reconstruction in the Era of Commercial Price Transparency: What Are We Paying For?

“…In this article, the authors leverage data made available through the Hospital Transparency Rule to analyze rates for microsurgical free flaps negotiated between hospitals and insurance companies. 1 Specifically, the authors explore 20,528 commercial rates across 675 hospitals for nine microsurgical free flaps based on CPT code. The key findings of this study are that rates vary widely between hospitals; are higher in more concentrated (less competitive) markets; are lower in safety net and teaching hospitals; and have an inconsistent correlation with value, outcomes, and equity.…”